TABLE 5 .
Shigella bactericidal responses in subjects immunized with S. flexneri 2a artificial invaplex or orally challenged with S. sonnei 53G in different clinical trials
| Vaccine or challenge strain, dose (type of study; ClinicalTrials registration no.) |
Subject IDa |
Day of study |
KI | Fold increase over baseline |
|---|---|---|---|---|
|
S. flexneri 2a artificial invaplex, 50 µg (vaccine trial; NCT02445963) |
30 | 0 | 1,073 | |
| 56 | 84,827 | 79 | ||
| 35 | 0 | 1,675 | ||
| 56 | 100,552 | 60 | ||
| 36 | 0 | 2,194 | ||
| 56 | 78,378 | 36 | ||
|
S. sonnei 53G, 1,500 CFU (CHIMb; NCT02816346) |
134 | 0 | 20 | |
| 14 | 6,107 | 305 | ||
| 135 | 0 | 20 | ||
| 14 | 6,202 | 310 | ||
| 137 | 0 | 381 | ||
| 14 | 24,246 | 64 |
a
ID, identification no.
b
CHIM, controlled human infection model.